Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ Origin: Appendix 5 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 1/03/13$

Name of entity	Name	of	entity	,
----------------	------	----	--------	---

Opthea Limited (Opthea)

ABN

32 006 340 567

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

⁺Class of ⁺securities issued or to be issued

Fully paid ordinary shares (**Shares**)

Number of *securities issued or to be issued (if known) or maximum number which may be issued Approximately 37,554,377 Shares under the institutional placement announced by Opthea on 3 April 2017 (**Placement**).

Approximately 10,832,720 Shares under the pro-rata accelerated non-renounceable entitlement offer announced by Opthea on 3 April 2017 (Entitlement Offer).

The exact number of Shares to be issued under the Placement and the Entitlement Offer, and the split of Shares between the institutional component of the Entitlement Offer (Institutional Entitlement Offer) and the retail component of the Entitlement Offer (Retail Entitlement Offer), is not known at the date of this Appendix 3B as it remains subject to (among other things) the determination of the Company, the

reconciliation of security holder entitlements and the effects of rounding.

21,000 Shares were also issued pursuant to the exercise of options.

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Same as existing quoted Shares.

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

Yes.

Shares issued under the Placement will not be entitled to participate in the Entitlement Offer.

In respect of the Placement and Entitlement Offer, \$0.93 per Share.

In respect of the issue of options, \$0.27 per share.

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

As described in the ASX announcement and investor presentation lodged with ASX on 3 April 2017 – namely, to raise capital to, amongst other things, fund clinical trials of Opthea's drug compound, OPT-302, in a phase 2B clinical trial for wet age related macular degeneration and a phase 2A clinical trial for treating diabetic macular edema patients.

21,000 Shares have been issued pursuant to the exercise of quoted options

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

ntity Yes urity v.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

28 November 2016

6c Number of *securities issued without security holder approval under rule 7.1

The exact number of shares to be issued is not known at the date of this Appendix 3B as it remains subject to (among other things) the determination of the Company, the reconciliation of security holder entitlements and the effects of rounding. Refer to item 2.

6d Number of *securities issued with security holder approval under rule 7.1A Refer to item 6c.

6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

N/A.

6f Number of *securities issued under an exception in rule 7.2

Refer to item 6c.

6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.

To be confirmed on the date of issue of Placement shares under Listing Rule 7.1A (scheduled for Wednesday, 12 April 2017) and calculated in accordance with Listing Rule 7.1A.3(b).

6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

See Annexure 1.

7 *Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.

29 March 2017 in respect of the exercise of quoted options.

12 April 2017 for Shares issued under the Placement and the Institutional Entitlement Offer.

3 May 2017 for Shares issued under the Retail Entitlement Offer.

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
After completion of	Fully paid ordinary
the Placement and	shares
Entitlement Offer,	
there will be	
approximately	
200,045,175 Shares	
on issue (based on	
151,658,078 Shares	
on issue as at the	
date of this	
Appendix 3B and the	
aggregate	
approximate number	
of Shares to be	
issued under the	
Placement and the	
Entitlement Offer as	
specified in item 2 of	
this Appendix 3B).	

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

48,254,922	Quoted options
------------	----------------

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
1,000,000	Unquoted options
	issued to Bell Potter
	Securities Limited
	pursuant to a
	Corporate Advisory
	Agreement.
7,000,000	Unquoted options
	issued to directors of
	Opthea.
2,625,000	Unquoted options
	issued to employees
	of Opthea.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Same as existing Shares, from the date of issue.

The ability of the Company to offer dividends (if any) is contingent on it making taxable profits. The determination of any dividend is at the absolute discretion of the directors.

Part 2 - Pro rata issue

Is security holder approval required?

No

Is the issue renounceable or non-renounceable?

Non-renounceable

- Ratio in which the *securities will be offered
- 1 Share for every 14 Shares held as at the record date for the Entitlement Offer.
- ⁺Class of ⁺securities to which the offer relates

Fully paid ordinary shares.

¹⁵ *Record date to determine entitlements

determine 7.00pm (AEST) on 5 April 2017.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No.
17	Policy for deciding entitlements in relation to fractions	Where fractions arise in the calculation of the shareholders' entitlements under the Entitlement Offer they will be rounded up to the next whole number of Shares.
18	Names of countries in which the entity has security holders who will not be sent new offer documents	Under the Retail Entitlement Offer, all countries other than Australia and New Zealand.
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	Under the Institutional Entitlement Offer, all countries other than Australia, New Zealand, the United States, Hong Kong, Singapore, Finland, Germany, Switzerland, Israel and the United Kingdom.
19	Closing date for receipt of acceptances or renunciations	Institutional Entitlement Offer closes Tuesday 4 April 2017.
		Retail Entitlement Offer closes 24 April 2017.
20	Names of any underwriters	The Institutional Entitlement Offer and Retail Entitlement Offer
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
2.4	Amount of any handling fee	N/A
24	payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on	N/A
-)	security holders' approval, the date of the meeting	14/11

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	No prospectus is being prepared. A retail offer booklet and entitlement and
		acceptance form in respect of the Retail
		Entitlement Offer will be sent to eligible
		retail security holders on or around 10 April 2017.
27	If the entity has issued options, and the terms entitle option	N/A
	holders to participate on	
	exercise, the date on which notices will be sent to option	
	holders	
28	Date rights trading will begin (if	NI/A
20	applicable)	14/11
	Determination of the 100	NT/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell	N/A
	their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a	N/A
	broker and accept for the	
	balance?	
32	How do security holders dispose	N/A
	of their entitlements (except by sale through a broker)?	
33	⁺ Issue date	Refer to item 7 of this Appendix 3B.
Part	t 3 - Quotation of sec	urities
	ed only complete this section if you are ap	
2.4	Type of teacyrities	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	
(u)	Securities described in Fair	· -
(b)	All other *securities	
	Example: restricted securities at the e	nd of the escrowed period, partly paid securities that become fully paid,

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to docum	e you are providing the information or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next	N/A	
	dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)	N/A	
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number N/A	N/A

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Company secretary	Date: 3 April 2017
Print name:	Mike Tonroe	
	== == == ==	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exc	ceeding 15% of capital
Step 1: Calculate "A", the base figures capacity is calculated	ure from which the placement
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	150,190,303 shares
 Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot 	15,500 shares (issued 18 May 2016) 30,900 shares (issued 7 October 2016) 1,400,375 shares (issued 3 February 2017) 21,000 shares (issued 29 March 2017)
 Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	None
"A"	151,658,078 shares

04/03/2013 Appendix 3B Page 11

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	22,748,711 shares
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	None.
Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	None.
Step 4: Subtract "C" from ["A" x "I placement capacity under rule 7.1 "A" x 0.15 Note: number must be same as shown in	B"] to calculate remaining 22,748,711 shares
Step 2	
Subtract "C"	None
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	Up to 22,748,711 shares
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional place	
Step 1: Calculate "A", the base fig capacity is calculated	gure from which the placement
"A"	151,658,078 shares
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	15,165,807
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month	None.

04/03/2013 Appendix 3B Page 13

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	15,165,807
Note: number must be same as shown in Step 2	
Subtract "E"	None.
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	Up to 15,165,807
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.